A Fresh Look at Merit Medical Systems (MMSI) Valuation After a Period of Flat Share Performance

Merit Medical Systems (MMSI) shares posted a mild increase today, with the stock closing just above $83. Over the past month, however, the stock price has stayed relatively flat, even as the healthcare sector has experienced broader shifts.

See our latest analysis for Merit Medical Systems.

After a tough stretch earlier this year, Merit Medical Systems has seen its share price settle just above $83. While short-term momentum is modest, the stock’s three-year total shareholder return of 25% points to notable long-term resilience and growth potential.

Curious how other medtech stocks are performing? Our Healthcare Stock Screener is a great way to discover the full list of innovators and market movers. See the full list for free.

With shares currently trading nearly 25% below analyst targets and recent financial performance showing only steady gains, investors may wonder if Merit Medical Systems is undervalued or if the market has already accounted for its future growth.

Most Popular Narrative: 19.8% Undervalued

The most followed narrative sees Merit Medical Systems trading well below its projected fair value, with the stock at $83.04 and a target of $103.55. This gap is fueled by expectations of earnings and margins outpacing the industry over the coming years.

The expanding global prevalence of chronic diseases and an aging population are increasing the need for interventional, diagnostic, and therapeutic medical procedures. Merit’s strong growth in cardiovascular and endoscopy segments, robust new product development, and recent acquisitions (such as Biolife and EndoGastric) position the company to capture a larger share of this growing market and drive sustained long-term revenue growth.

Read the complete narrative.

Want to know the growth blueprint behind this high valuation? The key element of this narrative is record-breaking earnings and a future profit multiple usually associated with tech leaders. Interested in which bold financial projections support that price target? Dive deeper to see the surprising numbers that drive this fair value calculation.

Result: Fair Value of $103.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, delays in reimbursement approvals and rising global trade tensions could slow revenue growth and present challenges to Merit Medical Systems' optimistic long-term outlook.

Find out about the key risks to this Merit Medical Systems narrative.

Another View: Are Shares Priced Too High?

Looking from another angle, the stock is trading at a price-to-earnings ratio of 41.3x, which is nearly double both the industry average of 28x and the peer average of 22.3x. This is well above the fair ratio of 22x, suggesting a clear valuation risk if expectations are not met. Are investors paying up for strong growth, or is caution warranted here?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Merit Medical Systems Narrative

If you see things differently or want to dig into the numbers yourself, you can build your own perspective on Merit Medical Systems in just a few minutes. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Merit Medical Systems.

Looking for Even Smarter Investment Ideas?

Smart investors do not let great opportunities pass them by. Use the Simply Wall Street Screener to find unique stocks shaping tomorrow’s market leaders before everyone else does.

• Unlock the potential of tomorrow’s disruptive tech by targeting these 26 AI penny stocks, which are setting the pace in artificial intelligence innovation.
• Boost your income strategy and secure reliable cash flow with these 24 dividend stocks with yields > 3%, which offer attractive yields above 3%.
• Seize bargains others may be missing by checking out these 837 undervalued stocks based on cash flows and uncover companies trading below their intrinsic value based on cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com